Dr. David is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
195 Little Albany St
New Brunswick, NJ 08901Phone+1 732-235-6777Fax+1 732-212-0713
Education & Training
- McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2006 - 2009
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2002 - 2005
- Columbia University Vagelos College of Physicians and SurgeonsClass of 2002
Certifications & Licensure
- NY State Medical License 2005 - 2026
- NJ State Medical License 2009 - 2025
- PA State Medical License 2024 - 2024
- IL State Medical License 2006 - 2011
- American Board of Internal Medicine Hematology
Clinical Trials
Publications & Presentations
PubMed
- 19 citationsPhase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies.Kevin A. David, Nigel P. Mongan, Christopher Smith, Lorraine J. Gudas, David M. Nanus
Cancer Biology & Therapy. 2010-05-01 - 4 citationsPredictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K Moyo
Journal of Hematology & Oncology. 2022-07-16 - 10 citationsClinical Studies in Hematologic MicrotransplantationKevin A. David, Dennis L. Cooper, Roger Strair
Current Hematologic Malignancy Reports. 2017-02-22
Abstracts/Posters
- Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell LymphomaKevin A. David, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0408Kevin A. David, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...Kevin A. David, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malig...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Blood Cancer Cures and Care: Addressing Leukemia and LymphomaSeptember 9th, 2021
- Analyzing Outcomes of Older Patients with Primary Central Nervous System LymphomaDecember 7th, 2020
- Retrospective Analysis Identifies Need for Better Classification of Rare LymphomaDecember 4th, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: